Lumvoa (veligrotug-vvze) is a humanised IgG1 monoclonal antibody against the insulin-like growth factor-1 receptor (IGF-1R), approved by the US FDA on 26 June 2026 under BLA 761530 for the treatment of thyroid eye disease (TED) regardless of disease activity or duration[1][2]. The labelled regimen is 10 mg/kg intravenously every 3 weeks for 5 infusions — a 12-week course, against 8 infusions over roughly 21 weeks for teprotumumab (Tepezza)[1][11].
It is not first-in-class: teprotumumab, approved in January 2020, was the first IGF-1R antagonist licensed for TED[12]. Lumvoa’s distinction is that its initial label already covers both the active and the chronic stage, supported by two separate phase 3 trials rather than a later supplement[3][5]. As of 29 August 2026 it is approved and launched in the United States only; the EU application is still under CHMP review and no CDSCO filing has been identified in India[8][9][10].
Snapshot verified against the FDA prescribing information, EMA CHMP meeting highlights and the CDSCO list of approved new drugs on 29 August 2026. Regulatory status changes; this is not a substitute for the full prescribing information.
What Lumvoa is approved for
The FDA-approved indication reads, in full: “LUMVOA is indicated for the treatment of thyroid eye disease regardless of thyroid eye disease activity or duration.”[1] The statement carries no restriction on symptom-onset window and no minimum Clinical Activity Score (CAS) — the two constraints that historically shaped TED prescribing. Both pivotal trials enrolled adults only (THRIVE from 18 years with no upper limit; THRIVE-2 from 18 to 75 years), so the evidence base behind the label is an adult one[4][5].
TED is a rare autoimmune orbitopathy, usually arising in Graves’ disease, in which immune-mediated inflammation and remodelling of orbital connective tissue produce proptosis (eye bulging), diplopia (double vision), pain, eyelid retraction and — in severe cases — compressive optic neuropathy. It is conventionally divided into an active inflammatory phase and a chronic or “burned-out” phase, and that division is exactly what the two-trial development programme was built to address[3][17].
Names and search variants
- Brand name: Lumvoa
- Non-proprietary name: veligrotug-vvze (the four-letter suffix is the FDA biologic suffix; the core name is veligrotug)
- Development code: VRDN-001
- Why older coverage looks different: the brand name was assigned close to approval, so 2024–2026 trial reporting refers only to “veligrotug” or “VRDN-001”[6]
- Not the same molecule as elegrobart (VRDN-003), Viridian’s separate subcutaneous candidate — see the pipeline section below[14]
Mechanism of action
The prescribing information describes veligrotug-vvze as “a humanized IgG1 monoclonal antibody that binds to IGF1R and inhibits IGF-1R signaling by blocking ligand-induced receptor autophosphorylation.”[1] In TED, IGF-1R is over-expressed on orbital fibroblasts and its signalling cross-talks with the thyroid-stimulating hormone receptor pathway implicated in Graves’-associated orbital inflammation. Blocking that receptor is intended to reduce the abnormal fibroblast activation driving tissue expansion.
On “full antagonist” versus “partial antagonist”. This distinction does not come from the FDA label — it comes from a peer-reviewed preclinical characterisation study. In head-to-head laboratory assays, veligrotug gave near-complete inhibition of IGF-1 binding at concentrations of 50 nM and above, whereas teprotumumab plateaued at roughly 50% inhibition; the two antibodies were shown to have overlapping but distinct binding epitopes, and veligrotug did not bind the insulin receptor[6]. That is a real, published in vitro finding. It is not evidence of superior clinical outcome: no head-to-head clinical trial between veligrotug and teprotumumab has been conducted, and no such comparison can be drawn from the separate trial programmes[17].
Clinical trial evidence
The BLA was supported by two global, randomised, double-masked, placebo-controlled phase 3 trials. Across both, 200 patients received Lumvoa and 101 received placebo[1]. Use the tabs to compare them.
THRIVE (NCT05176639) — moderate-to-severe active TED
113 adults with onset within 15 months, proptosis at least 3 mm above normal and CAS of at least 3, randomised 2:1 to veligrotug 10 mg/kg (n=75) or placebo (n=38), given as 5 IV infusions every 3 weeks. Study sites spanned the United States, Australia, France, Germany, Poland, Spain and the United Kingdom[4]. Week-15 results, all P less than 0.001 versus placebo[1][3]:
Improvement was already measurable at week 3, after a single infusion. Treatment discontinuation was 4%[3].
THRIVE-2 (NCT06021054) — moderate-to-severe chronic TED
188 adults aged 18 to 75 with ocular signs or symptoms beginning more than 15 months before screening and any CAS from 0 to 7, randomised 2:1 to veligrotug (n=125) or placebo (n=63) on the identical 5-infusion regimen. The trial ran from November 2023, with primary completion in November 2024 and study completion in July 2025[5]. Week-15 results per the approved label[1]:
This is the trial that carries the chronic half of the label. It is also the reason the day-one indication is broader than teprotumumab’s original 2020 indication, which covered active disease only until the April 2023 label update[12].
A note on sourcing. THRIVE-2 has no full peer-reviewed journal publication indexed in PubMed as of 29 August 2026. Its results are, however, posted on ClinicalTrials.gov and reproduced in the FDA-approved label’s Clinical Studies section — both primary sources. Figures here are taken from those, not from conference abstracts or company slides[1][5].
How long does the effect last?
THRIVE followed patients to week 52. At that point 70% of initial proptosis responders had maintained their response, and the investigators reported no change in the safety profile between week 15 and week 52, with most adverse events mild and resolving and no serious treatment-related adverse events[3].
That is the longest controlled follow-up currently published for this molecule. Two limitations matter when quoting it:
- It is a within-trial durability figure among responders, not a comparison against placebo at 52 weeks.
- Equivalent 52-week durability data for the chronic population (THRIVE-2) have not been published, so durability in chronic disease should be treated as not yet established rather than assumed[5].
What kind of approval is this?
This is a traditional (full) approval based on two adequately powered, randomised, double-masked, placebo-controlled trials that met pre-specified primary and secondary endpoints — not an accelerated approval resting on a surrogate marker[1][16]. For anyone assessing the strength of a 2026 novel-drug approval, that distinction is the single most informative fact on the page.
Two honest caveats:
- Both pivotal trials excluded patients previously treated with another anti-IGF-1R therapy[4][5]. The label does not exclude them, but there is no trial evidence in that group.
- Both excluded patients with inflammatory bowel disease and with clinically significant baseline hearing loss or ear pathology — precisely the two organ systems that carry the class safety signal[4][5]. Real-world populations will include such patients.
Does the trial evidence cover your patient profile?
The label is broad; the evidence base is narrower. Select a stage and a treatment history to see which pivotal trial, if any, actually studied that combination.
1. Disease stage
2. Prior anti-IGF-1R antibody (e.g. teprotumumab)
Select one option in each row
The result shows which phase 3 trial enrolled that profile and what was measured in it.
Source: FDA prescribing information and ClinicalTrials.gov protocol records.
Educational tool, not clinical decision support. This selector reports which trial population a profile matches. It does not recommend, exclude or dose any therapy. Treatment decisions rest with the prescribing physician working from the full prescribing information.
Safety, warnings and required monitoring
The points below are label facts, drawn from the approved prescribing information[1]. They are regulatory content, not treatment guidance.
Hearing impairment. Lumvoa may cause severe hearing impairment including hearing loss, which in some cases may be permanent. The label directs that hearing be assessed before, during and after treatment. In the pooled trial data hearing impairment was reported in 15% of Lumvoa patients versus 6% on placebo.
Inflammatory bowel disease. Monitor all patients for signs and symptoms of IBD, including those with no history of IBD. The label instruction is unambiguous: if IBD is suspected, discontinue Lumvoa. This is a discontinuation instruction, not merely a prompt to investigate.
Adverse reactions occurring in 5% or more of patients
Scroll sideways to see the placebo column →
| Adverse reaction | Lumvoa (n=200) | Placebo (n=101) | Note |
|---|---|---|---|
| Muscle spasms | 40% | 7% | Largest absolute difference in the table |
| Headache | 17% | 14% | Small margin over placebo |
| Hearing impairment | 15% | 6% | Boxed in Warnings and Precautions; may be permanent |
| Hyperglycaemia | 13% | 5% | Warnings section cites 12%; assess glucose before each infusion |
| Fatigue | 13% | 11% | Small margin over placebo |
| Diarrhoea | 11% | 7% | Consider in the context of the IBD warning |
| Ear discomfort | 10% | 3% | Otologic signal alongside hearing impairment |
| Infusion-related reaction | 9% | 2% | Usually mild to moderate; manageable with premedication |
| Nausea | 8% | 6% | Small margin over placebo |
| Nasopharyngitis | 7% | 1% | — |
| Creatine phosphokinase increased | 6% | 1% | Laboratory finding |
| Dry skin | 6% | 2% | — |
| Hypertension | 6% | 5% | Small margin over placebo |
| Menstrual disorders | 29% (24/82) | 6% (2/33) | Denominator is menstruating women only |
Two further label requirements sit outside the adverse-reaction table. Hyperglycaemia: assess for elevated blood glucose and symptoms before each infusion, continue monitoring during and after treatment, and ensure adequate glycaemic control in patients with diabetes[1]. Embryo-fetal toxicity: Lumvoa should not be used during pregnancy, and patients of reproductive potential should use effective contraception during treatment and for 6 months after the last dose[1].
Dosing and administration
Label information only. The treating physician determines the regimen for an individual patient.
- Dose: 10 mg/kg by intravenous infusion every 3 weeks, for a total of 5 infusions[1]. Unlike teprotumumab, the dose does not escalate after the first infusion.
- Infusion time: 45 minutes for the first infusion; if well tolerated, subsequent infusions may be given over a minimum of 30 minutes[1].
- Preparation: dilute into 250 mL of 0.9% sodium chloride, removing an equivalent volume first; mix by gentle inversion to avoid foaming; do not shake[1].
- Diluted-solution hold time: up to 4 hours at room temperature or up to 72 hours refrigerated at 2 to 8 °C[1].
- Do not administer as an IV push or bolus, and do not infuse concomitantly with other agents[1].
Lumvoa vs Tepezza: what the two labels actually say
Both comparisons below are drawn from each product’s own FDA prescribing information[1][11]. No head-to-head trial exists. Adverse-event percentages come from separate trial programmes with different populations, and cross-trial comparison of safety rates is not methodologically valid — the columns are set side by side so that each label can be read accurately, not so that the numbers can be subtracted from one another.
Scroll sideways to see both columns →
| Label attribute | Lumvoa (veligrotug-vvze) | Tepezza (teprotumumab-trbw) |
|---|---|---|
| Approved indication | TED regardless of activity or duration, from first approval (Jun 2026) | TED regardless of activity or duration — active disease only until the Apr 2023 label update |
| Dose | 10 mg/kg for all 5 infusions | 10 mg/kg first infusion, then 20 mg/kg |
| Number of infusions | 5, every 3 weeks (12-week course) | 8, every 3 weeks (approx. 21-week course) |
| Infusion duration | 45 min first; minimum 30 min thereafter | At least 90 min for the first two; minimum 60 min thereafter |
| Infusion reactions (own label) | Approximately 9% | Approximately 4% |
| Hyperglycaemia (own label) | 12% | 10%, two-thirds with pre-existing diabetes or glucose intolerance |
| Hearing impairment (own label) | 15% vs 6% placebo in trials | 10% in trials; 13% in post-approval trials |
| IBD instruction | Monitor all patients; discontinue if IBD is suspected | Monitor all patients; discontinue if exacerbation is suspected |
| Hearing monitoring | Before, during and after treatment | Before, during and after treatment |
| Contraception after last dose | 6 months | 6 months |
| Delivery format in current label | IV infusion only | IV infusion only; a subcutaneous on-body injector reported positive phase 3 topline in Apr 2026 but is not FDA-approved |
The verifiable differentiators are therefore chair time and course length — 5 shorter infusions over 12 weeks against 8 longer infusions over about 21 weeks — and the breadth of the day-one label. Whether full versus partial IGF-1R antagonism produces a clinical difference remains unestablished by any published head-to-head data[6][17]. Readers comparing 2026 approvals across therapy areas may also find the running FDA novel drug approvals tracker for 2026 useful — Lumvoa is entry 23 on that list.
Regulatory timeline
- 10 September 2024THRIVE phase 3 topline reportedPositive results in active TED[7]
- 16 December 2024THRIVE-2 phase 3 topline reportedPositive results in chronic TED, completing the two-stage evidence package[7]
- 7 May 2025FDA Breakthrough Therapy DesignationGranted on the strength of the phase 3 proptosis and diplopia data[7]
- 20 May 2025THRIVE 52-week durability data70% of initial proptosis responders maintained response at week 52[3][7]
- October 2025BLA submitted to the FDASubmission announced 3 November 2025 — a step the original version of this article omitted[7]
- 22 December 2025BLA accepted; Priority Review grantedPDUFA target action date set at 30 June 2026[7][8]
- January 2026EU marketing authorisation application submittedFiled with the European Medicines Agency[8]
- February 2026MAA validated; CHMP review beginsFormal start of the European assessment[8]
- 26 June 2026FDA approval and US launchApproved four days ahead of the PDUFA date, with immediate commercial launch[1][2]
- As of 29 August 2026EU decision still pendingVeligrotug does not appear among medicines recommended for approval in CHMP meeting highlights through the 20 to 23 July 2026 meeting[9]
Availability outside the United States, including India
- United States: approved 26 June 2026 and commercially launched by Viridian[2].
- European Union: the marketing authorisation application was submitted in January 2026 and validated in February 2026. Veligrotug is not listed among medicines recommended for approval in the CHMP meeting highlights published through July 2026, so no opinion had been adopted as of this update[8][9].
- India: no CDSCO approval for veligrotug or Lumvoa has been identified. Worth stating precisely: CDSCO’s published “List of New Drugs approved in year 2026 to till date” carries a release date of 12 March 2026, which itself predates the US approval — so the absence of an entry reflects both a genuine lack of approval and a publication lag in the source list[10]. For a first-in-country specialty biologic, an Indian filing would ordinarily follow the US and EU decisions rather than run alongside them.
Why “approved” is a jurisdiction-specific word. Indian importers, hospital procurement teams and medical-tourism intermediaries occasionally treat a US approval as though it settles availability. It does not. Import of an unapproved new drug for a named patient in India runs through a separate CDSCO route with its own documentation, and no such pathway is asserted here. Anyone advising on this should work from the current CDSCO position rather than from US or EU status[10].
Pricing
Viridian did not publish a wholesale acquisition cost in its approval announcement. Following approval, financial press reporting cited a Jefferies analyst placing the course price at approximately US$450,000, at parity with teprotumumab[15]. Treat this as analyst commentary, not an official WAC disclosure — directional rather than definitive. No India-specific or other-market pricing has been announced, and none would be expected before a local filing.
What comes next in this class
Two subcutaneous programmes are competing to remove the infusion chair from TED treatment altogether, and neither is FDA-approved as of 29 August 2026:
- Elegrobart (VRDN-003) — Viridian’s own subcutaneous autoinjector candidate, with positive phase 3 topline results reported from REVEAL-1 in active TED (March 2026) and REVEAL-2 in chronic TED (May 2026). The company has stated it anticipates BLA submission in the first quarter of 2027[8][14]. If it reaches the market, Viridian would hold both an IV and a subcutaneous option in the same indication.
- Subcutaneous Tepezza — Amgen reported positive phase 3 topline results for an on-body-injector formulation in moderate-to-severe active TED in April 2026. It is not FDA-approved[13].
The strategic reading is that Lumvoa’s IV convenience advantage over Tepezza has a limited shelf life. Course length and chair time are the differentiators today; a subcutaneous device would reset that comparison entirely.
What this means from a QA, RA and pharmacovigilance perspective
Four points that matter beyond the efficacy headline:
- Two adequately powered trials to secure one unrestricted label is a deliberate, expensive strategy. Viridian ran separate active-disease and chronic-disease phase 3 trials rather than approving narrow and expanding later, which is the path teprotumumab took across 2020 to 2023[3][12]. The label breadth on day one is the return on that decision — a useful precedent for any sponsor weighing indication scope against development cost.
- The safety profile is a class effect, not a new signal. Hearing impairment, hyperglycaemia, infusion reactions and IBD all appear in the teprotumumab label too[11]. Centres that already built baseline audiometry, glucose checks and IBD screening around Tepezza can transfer that infrastructure with minimal modification — though the monitoring schedules and infusion times differ, so protocols need rewriting rather than reusing.
- Post-marketing surveillance has a defined blind spot. Both pivotal trials excluded patients with pre-existing IBD and with clinically significant baseline hearing loss[4][5]. Those are exactly the patients a real-world safety database will start accumulating from launch. Pharmacovigilance plans built only from trial-population expectations will under-anticipate that.
- Jurisdictional lag is the operative constraint, not efficacy. The FDA has acted; the CHMP has not; CDSCO has no filing on record. For a specialty biologic, infusion-centre logistics and payer coverage take real time to stand up in each market — a materially different launch dynamic from an oral generic. If you are mapping regulatory sequencing, the regulatory compliance advisory work we do covers exactly this gap between an approval headline and an operational filing plan.
Frequently asked questions
Lumvoa (veligrotug-vvze) is an intravenous biologic approved by the US FDA on 26 June 2026 for the treatment of thyroid eye disease, regardless of how active the disease is or how long the patient has had it. It is an IGF-1R antagonist monoclonal antibody given as five infusions over twelve weeks.
No. Teprotumumab (Tepezza) was approved in January 2020 and was the first IGF-1R antagonist licensed for thyroid eye disease. Lumvoa is the second. What is new is that Lumvoa’s first approval already covers both active and chronic disease, whereas teprotumumab’s label was expanded to cover chronic disease only in April 2023.
The verifiable differences are the treatment schedule and the label. Lumvoa is five infusions of 10 mg/kg over twelve weeks, with the first infusion over 45 minutes; Tepezza is eight infusions over about twenty-one weeks with a dose escalation to 20 mg/kg and infusions of at least 90 minutes initially. No head-to-head trial has compared the two, so relative efficacy and safety cannot be determined.
The prescribing information highlights severe hearing impairment including hearing loss that may be permanent, hyperglycaemia, infusion reactions, and inflammatory bowel disease. Hearing must be assessed before, during and after treatment, and blood glucose assessed before infusions. If inflammatory bowel disease is suspected, the label directs that Lumvoa be discontinued.
Not as of 29 August 2026. No CDSCO approval for veligrotug or Lumvoa has been identified in the published list of approved new drugs. It is currently a US-approved and US-launched product, with a European application still under CHMP review and no European decision announced.
Viridian has not published an official US list price. Financial press reporting after approval cited a Jefferies analyst estimate of roughly 450,000 US dollars per treatment course, at parity with Tepezza. That figure is analyst commentary rather than a formal wholesale acquisition cost disclosure, and no India or other-market pricing has been announced.
Two randomised, double-masked, placebo-controlled phase 3 trials: THRIVE in active disease (113 patients) and THRIVE-2 in chronic disease (188 patients). At week 15 the proptosis responder rate was 70 percent against 5 percent on placebo in THRIVE, and 57 percent against 8 percent in THRIVE-2. This was a traditional full approval, not an accelerated approval on a surrogate endpoint.
In THRIVE, which followed patients to week 52, seventy percent of initial proptosis responders had maintained their response at one year, with no change in the safety profile over that period. Equivalent 52-week data for the chronic disease population studied in THRIVE-2 have not been published, so durability in chronic disease should not be assumed.
Related on Laafon
- FDA novel drug approvals 2026 — live trackerSortable table of every CDER novel approval this year; Lumvoa is entry 23.
- Tryptyr (acoltremon) for dry eye diseaseThe other recent ophthalmology approval covered here, and a contrast in delivery route and cost tier.
- Trutakna — dual BAFF/APRIL biologic for IgA nephropathyAnother 2026 biologic approval, useful if you are tracking BLA-route approvals rather than NDAs.
- Loargys (pegzilarginase-nbln) for arginase 1 deficiencyA rare-disease enzyme replacement approval, for comparison on evidence standards in small populations.
- All FDA novel drug analysesThe full category archive of approval breakdowns on this site.
- About the authorBackground, qualifications and the review approach applied to regulatory content here.
Mapping a regulatory pathway of your own?
Whether a molecule is filed as an NDA or a BLA, and how its evidence package is structured across indications, decides how long the approval takes and how broad the label ends up. That planning is what we do.
References
- US Food and Drug Administration. LUMVOA (veligrotug-vvze) injection, for intravenous use — highlights of prescribing information. BLA 761530. Silver Spring (MD): FDA; June 2026. Available from: accessdata.fda.gov. Accessed August 2026.
- Viridian Therapeutics, Inc. Viridian Therapeutics announces U.S. FDA approval and launch of Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease. News release. 26 June 2026. Available from: viridiantherapeutics.com. Accessed August 2026.
- Yen MT, Cockerham K, Saeed P, et al. THRIVE: a phase 3, randomized, double-masked, placebo-controlled study of veligrotug for active thyroid eye disease. Ophthalmology. 2026;133(9):1085–1096. Available from: doi.org/10.1016/j.ophtha.2026.04.022. Accessed August 2026.
- ClinicalTrials.gov. A safety, tolerability, and efficacy study of veligrotug (VRDN-001) in participants with thyroid eye disease (THRIVE). NCT05176639. Bethesda (MD): National Library of Medicine. Available from: clinicaltrials.gov/study/NCT05176639. Accessed August 2026.
- ClinicalTrials.gov. An efficacy, safety, and tolerability study of veligrotug (VRDN-001) in participants with chronic thyroid eye disease (THRIVE-2). NCT06021054. Bethesda (MD): National Library of Medicine. Available from: clinicaltrials.gov/study/NCT06021054. Accessed August 2026.
- Kaplan R, Zhao Y, Tsai J, et al. Preclinical pharmacology, pharmacokinetics, and pharmacodynamics of veligrotug, a full antagonist antibody to the IGF-1 receptor in development for thyroid eye disease. MAbs. 2025;17(1):2585616. Available from: doi.org/10.1080/19420862.2025.2585616. Accessed August 2026.
- Drugs.com. Lumvoa (veligrotug-vvze) FDA approval history. Available from: drugs.com/history/lumvoa.html. Accessed August 2026.
- Viridian Therapeutics, Inc. Viridian Therapeutics reports first quarter 2026 financial results and highlights recent progress. News release. 5 May 2026. Available from: investors.viridiantherapeutics.com. Accessed August 2026.
- European Medicines Agency. Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20–23 July 2026. Amsterdam: EMA; 2026. Available from: ema.europa.eu. Accessed August 2026.
- Central Drugs Standard Control Organisation. List of approved new drugs. New Delhi: CDSCO, Government of India. Available from: cdsco.gov.in. Accessed August 2026.
- US Food and Drug Administration. TEPEZZA (teprotumumab-trbw) for injection — highlights of prescribing information. BLA 761143, supplement 030. Silver Spring (MD): FDA; 2025. Available from: accessdata.fda.gov. Accessed August 2026.
- Drugs.com. Tepezza (teprotumumab-trbw) FDA approval history. Available from: drugs.com/history/tepezza.html. Accessed August 2026.
- Amgen Inc. Amgen announces positive topline phase 3 results for subcutaneous TEPEZZA in adults living with moderate-to-severe active thyroid eye disease. News release. 6 April 2026. Available from: amgen.com. Accessed August 2026.
- Viridian Therapeutics, Inc. Viridian Therapeutics announces positive topline results from elegrobart phase 3 REVEAL-2 clinical trial in chronic thyroid eye disease. News release. 5 May 2026. Available from: investors.viridiantherapeutics.com. Accessed August 2026.
- BioPharma Dive. Viridian may have edge over Amgen in eye drug showdown, analysts argue. 2026. Available from: biopharmadive.com. Accessed August 2026.
- US Food and Drug Administration. Novel drug approvals for 2026. Available from: fda.gov. Accessed August 2026.
- Zhao Z, Aakalu VK. Veligrotug: expanding treatment options for thyroid eye disease. Ophthalmology. 2026;133(9):1097–1098. Available from: doi.org/10.1016/j.ophtha.2026.06.028. Accessed August 2026.
Disclaimer. This article is technical and educational content written for pharmaceutical, regulatory-affairs and quality professionals. It is not medical advice, not a substitute for the full FDA prescribing information, and not investment advice. Approval status, labelling and pricing change; pharmacopoeial texts and Indian statutory instruments are revised frequently. Verify any operative detail against the current primary source before acting on it. Laafon Galaxy Pharmaceuticals has no commercial relationship with Viridian Therapeutics or Amgen.
